The Atopic Dermatitis Vaccinia Network (ADVN) is an NIH-funded multi-center network charged with better understanding the susceptibility of eczema patients to the vaccinia infection and to search for ways to protect against it. Atopic dermatitis is another name for eczema, an allergic skin condition that causes itchy, inflamed and cracked skin.
The ADVN researchers believed that they might be able to identify eczema patients at high risk for these infections and to obtain clues about the mechanisms of susceptibility by studying a large cohort of patients who had suffered eczema herpeticum, the herpes simplex viral skin infections. They examined a wide variety of demographic, pathologic and biologic characteristics in 901 subjects, 138 of whom had suffered eczema herpeticum.
They found that eczema patients susceptible to herpes simplex infections had more severe disease, earlier age of disease onset, more frequent history of other allergic diseases such as food allergy, asthma and hay fever, more allergic biomarkers, and more frequent skin infections with other microbes.
"These characteristics associated with eczema herpeticum should help us identify young patients at greater risk for eczema herpeticum so that we can be more vigilant with them and better equipped to prevent this serious complication of eczema," said Dr. Leung.
The greater allergic disease and sensitization, as well as infection by other microbes, point to a potential mechanism for the increased susceptibility to viral skin infections. An emerging model of eczema highlights the importance of skin-barrier defects and a lack of antimicrobial proteins among eczema patients. The skin-barrier defect is believed to result in the greater allergic sensitization among eczema patients in general. The even higher allergic sensitization among EH patients sugges
|Contact: William Allstetter|
National Jewish Medical and Research Center